"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
- Clinician Information:
Mannitol IV Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Mannitol I.V. (mannitol injection) is used to increase urine production, and to treat or prevent medical conditions that are caused by an increase in body fluids/water (e.g., cerebral edema, glaucoma, kidney failure). It is a diuretic. This medication is available in generic form. Common side effects include headache, nausea, diarrhea, vomiting, dry mouth, thirst, dehydration, and irritation/pain/swelling at the injection site.
The usual adult dosage of Mannitol ranges from 50 to 200 g in a 24-hour period, but in most instances an adequate response will be achieved at a dosage of approximately 100 g/24 hours. Mannitol may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, Mannitol should be used only if prescribed. Consult your doctor before breastfeeding.
Our Mannitol I.V. (mannitol injection) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Mannitol IV FDA Prescribing Information: Side Effects
Adverse reactions more commonly reported during or after the infusion of mannitol (mannitol (mannitol injection) injection) include: Pulmonary congestion, fluid and electrolyte imbalance, acidosis, electrolyte loss, dryness of mouth, thirst, marked diuresis, urinary retention, edema, headache, blurred vision, convulsions, nausea, vomiting, rhinitis, arm pain, skin necrosis, thrombophlebitis, chills, dizziness, urticaria, dehydration, hypotension, tachycardia, fever and angina-like chest pains.
Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
Read the entire FDA prescribing information for Mannitol IV (Mannitol Injection) »
Additional Mannitol IV Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.